The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Open accessAbstract
OBJECTIVE: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD). METHODS: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the Neuropsychological Test Battery (NTB) and Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale. The primary analysis compared 250 mg (n =84) to placebo (n =82) after an imbalance of infections and deaths led to early discontinuation of the 2 higher dose groups. RESULTS: The 250 mg dose demonstrated acceptable safety. The primary efficacy analysis at 78 weeks revealed no significant differences between the treatment groups on the NTB or ADCS-ADL. Brain ventricular volume showed a small but significant increase in the overall 250 mg group (p =0.049). At the 250 mg dose, scyllo-inositol concentrations increased in CSF and brain and CSF Aβx-42 was decreased significantly compared to placebo (p =0.009). CONCLUSIONS: Primary clinical efficacy outcomes were not significant. The safety and CSF biomarker results will guide selection of the optimal dose for future studies, which will target earlier stages of AD. CLASSIFICATION OF EVIDENCE: Due to the small sample sizes, this Class II trial provides insufficient evidence to support or refute a benefit of ELND005.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oral drug, scyllo-inositol is a Aβ42 aggregation inhibitor that was studied in AD subjects (ELND005). A clinical study (phase 2) in patients with AD found no confirmation of ELND005′s clinical benefit, and the study was stopped due to severe toxicity concerns (Salloway et al., 2011).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2011
In the citing paper
“Further development of the agent at a lower dose has not progressed in the last 8 years.50”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [50]
In the citing paper
“A phase 2 clinical trial in patients with AD did not provide evidence to support a clinical benefit of ELND005 while severe toxicity issues (infections) forced the cessation of the study.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [50]
In the citing paper
“The last Aβ42 aggregation inhibitor which was tested in humans was the oral agent scyllo-inositol (ELND005).”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis
Smith, S. M., Zhang, Y., Jenkinson, M., Chen, J. M., Matthews, P. M., Federico, A., & Stefano, N. D. (2002) · NeuroImage · doi:10.1006/nimg.2002.1040 · Cited by 2,013
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Cited by
Sorted by citations
Items 101–200 of 260
Moussallieh, F., Elbayed, K., Chanson, J., Rudolf, G., Piotto, M., Seze, J. D., & Namer, I. J. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513504638 · Cited by 40
Innate Immune and Fungal Model of Alzheimer’s Disease
Parady, B. (2018) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180073 · Cited by 40
“Conversely, treatments for AD are often aimed at reducing the deposits of A in the brain [45, 46].”
BackgroundShukla, R., Singh, A., Handa, M., Flora, S. J. S., & Kesharwani, P. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.011 · Cited by 40
Advancements in the treatment of agitation in Alzheimer’s disease
Antonsdottir, I. M., Smith, J. S., Keltz, M., & Porsteinsson, A. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1059422 · Cited by 40
“ELND005 has been shown to have amyloid and myoinositol-lowering effects [28] and beneficial trends on agitation and aggression as secondary symptoms of AD [29].”
BackgroundRafii, M. S., Skotko, B. G., McDonough, M. E., Pulsifer, M. B., Evans, C. L., Doran, E. W., Muranevici, G., Kesslak, P. J., Abushakra, S. R., Lott, I. T., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160965 · Cited by 41
“mg qd and 250 mg bid dose were selected due to their acceptable long-term safety and beneficial trends on cognition in mild AD within the general population [17].”
InfluentialCombination therapy in a transgenic model of Alzheimer's disease
Aytan, N., Choi, J., Carreras, I., Kowall, N. W., Jenkins, B. G., & Dedeoglu, A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.10.001 · Cited by 37
“Scyllo-inositol has recently been in human clinical trials for the treatment of patients with mild to moderate AD (Salloway et al., 2011).”
BackgroundGuo, T., Dukart, J., Brendel, M., Rominger, A., Grimmer, T., Yakushev, I. Y., & Initiative, A. D. N. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.05.013 · Cited by 37
Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer’s disease patients?
Panza, F., Lozupone, M., Bellomo, A., & Imbimbo, B. P. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100948 · Cited by 34
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 36
“However, the molecule failed to reach desired endpoints in trials, not showing an improvement in behavioral or cognitive functions compared to placebo (NCT01735630) [50].”
BackgroundLiu, M., Jevtic, S. D., Markham-Coultes, K., Ellens, N. P. K., O’Reilly, M. A., Hynynen, K., Aubert, I., & McLaurin, J. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.015 · Cited by 35
Murakami, K., & Irie, K. (2019) · Molecules · doi:10.3390/molecules24112125 · Cited by 31
“These failed studies include EGCG from green tea (ClinicalTrials.gov Identifier: NCT00951834; trial results were not published, but see Reference [85]), scyllo-inositol from coconut palm (e.g., ClinicalTrials.gov Identifier: NCT01735630) [86], and curcumin from turmeric (e.g., ClinicalTrials.gov Identifier: NCT0009971…”
BackgroundAmyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type
Kamp, J. A., Moursel, L. G., Haan, J., Terwindt, G. M., Lesnik Oberstein, S. A. M. J., van Duinen, S. G., & van Roon-Mom, W. M. C. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0008 · Cited by 36
“clinical efficiency outcomes in a phase two clinical trial of AD patients using 250 mg Scyllo-inositol were not significantly different from placebo, and higher dose studies were discontinued due to increased infections and mortalities (Salloway et al., 2011).”
BackgroundDiscontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Fu, B., Huang, X., Ma, J., Chen, Q., Zhang, Q., & Yu, P. (2021) · LWT · doi:10.1016/j.lwt.2021.112553 · Cited by 30
Ahmed, M., Malik, M., Teselink, J., Lanctôt, K. L., & Herrmann, N. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00668-7 · Cited by 29
Protein aggregation in neurodegenerative diseases
Wang, J., Dai, L., & Zhang, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003802 · Cited by 29
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Parsons, C. G., & Rammes, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313832 · Cited by 29
“A phase II clinical trial evaluating safety, efficacy, and effects on biomarkers of ELND-005 in mild-to-moderate AD patients has been completed [132].”
BackgroundInvestigational drugs for treating agitation in persons with dementia
Garay, R. P., Citrome, L., Grossberg, G. T., Cavero, I., & Llorca, P. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1193155 · Cited by 27
“The remaining six phase II trials fulfilled the inclusion criteria and included the following four investigational compounds: the cannabinoid delta-THC [45–50], the selective α2c-adrenoceptor antagonist ORM-12741 [51,52], the inositol isomer ELND005 [53–57], and the 5-HT1A/1B receptor agonist eltoprazine [58–60] (Tabl…”
BackgroundResultInfluentialMeulenbroek, O., O'Dwyer, S., de Jong, D., van Spijker, G. J., Kennelly, S., Cregg, F., Rikkert, M. G. M. O., Abdullah, L. I., Wallin, A., Walsh, C., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011584 · Cited by 27
Lee, D., Lee, W.-S., Lim, S., Kim, Y. K., Jung, H., Das, S., Lee, J., Luo, W., Kim, K., & Chung, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-14559-7 · Cited by 29
Culibrk, R. A., & Hahn, M. S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.583884 · Cited by 28
“…attenuation of Aβ accumulation when such therapies were administered to a variety of transgenic disease models (Wiessner et al., 2011; Eketjäll et al., 2016), these results were rarely—if ever—recapitulated in clinical trials (Holmes et al., 2008; Salloway et al., 2011; Egan et al., 2018).”
BackgroundYanckello, L. M., Hoffman, J. D., Chang, Y., Lin, P., Nehra, G., Chlipala, G. E., McCulloch, S. D., Hammond, T. C., Yackzan, A. T., Lane, A. N., et al. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2021.1889452 · Cited by 28
“Scyllo-inositol has been shown to inhibit Aβ42 aggregation in both animal and clinical trials [25,26], suggesting that inulin”
Alzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials
Rafii, M. S. (2020) · CNS Drugs · doi:10.1007/s40263-020-00740-6 · Cited by 26
Binding Mechanism of Inositol Stereoisomers to Monomers and Aggregates of Aβ(16-22)
Li, G., & Pomès, R. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp311350r · Cited by 25
Ramp, P., Lehnert, A., Matamouros, S., Wirtz, A., Baumgart, M., & Bott, M. H. (2021) · Metabolic Engineering · doi:10.1016/j.ymben.2021.06.011 · Cited by 24
Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder
Catania, M., Giaccone, G., Salmona, M., Tagliavini, F., & Fede, G. D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00317 · Cited by 25
“, 2018) and in few clinical trials (Salloway et al., 2011; Cummings et al., 2016; Hey et al., 2018).”
BackgroundPeroxidase activity of heme bound amyloid β peptides associated with Alzheimer's disease
Roy, M., Pal, I., Nath, A. K., & Dey, S. G. (2020) · Chemical Communications · doi:10.1039/c9cc09758a · Cited by 24
Michon, C., Kang, C.-M., Karpenko, S., Tanaka, K., Ishikawa, S., & Yoshida, K. (2020) · Communications Biology · doi:10.1038/s42003-020-0814-7 · Cited by 22
Fauvelle, F., Boccard, J., Cavarec, F., Depaulis, A., & Deransart, C. (2015) · Journal of Proteome Research · doi:10.1021/pr501309b · Cited by 20
Dementia: new criteria but no new treatments
Sperling, R. A., & Johnson, K. A. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70272-1 · Cited by 22
Rashid, U., & Ansari, F. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50002-7 · Cited by 23
Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease
Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 20
“Another anti-aggregation agent, scyllo-inositol, was also of no benefit to cognition in a phase 2 trial [20].”
BackgroundAmyloid Disassembly: What Can We Learn from Chaperones?
Almeida, Z. L., & Brito, R. M. M. (2022) · Biomedicines · doi:10.3390/biomedicines10123276 · Cited by 21
“In addition, treatment with scyllo-inositol has reversed cognitive deficits, reduced synaptic toxicity and lowered amyloid-β (Aβ) fibrils and plaques in a mouse model [96], and in clinical trials for Alzheimer’s disease (AD) [97].”
BackgroundSouvenaid®: A new approach to management of early Alzheimer's disease
Ritchie, C. W., Bajwa, J., Coleman, G., Hope, K. W., Jones, R. W., Lawton, M., Marven, M., & Passmore, P. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0411-2 · Cited by 20
Tajmim, A., Cuevas-Ocampo, A. K., Siddique, A. B., Qusa, M. H., King, J. A., Abdelwahed, K. S., Sonju, J. J., & Sayed, K. A. E. (2021) · Nutrients · doi:10.3390/nu13051702 · Cited by 21
“Although researchers are trying to focus the mainstream AD drug discovery and development efforts on the components or therapies directly involved in AD pathology, compelling evidence points to the low success rate of AD therapeutics because of toxicity and weak clinical efficacy concerns [45,46].”
BackgroundTreatment of Alzheimer’s Disease: Current Management and Experimental Therapeutics
Honig, L. S., & Boyd, C. D. (2013) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-013-0056-3 · Cited by 19
“Drug treatments designed to decrease Aβ fibrillization or aggregation, including homotaurine [50] and scyllo-inositol [51] have not proven effective.”
BackgroundKim, D., Kim, Y. S., Shin, D. W., Park, C., & Kang, J.-H. (2016) · Journal of Clinical Neurology · doi:10.3988/jcn.2016.12.4.381 · Cited by 20
Eleti, S. (2016) · PubMed · Cited by 19
Odorskaya, M. V., Мавлетова, Д. А., Nesterov, A. A., Tikhonova, O. V., Soloveva, N. A., Reznikova, D. A., Galanova, O. O., Vatlin, A. A., Slynko, N. M., Vasilieva, A. R., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1416688 · Cited by 23
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 20
Kang, J., Ryoo, N., Shin, D. W., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.6.447 · Cited by 18
Barreto, P. D. S., Denormandie, P., Lepage, B., Armaingaud, D., Rapp, T., Chauvin, P., Vellas, B. J., & Rolland, Y. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.02.004 · Cited by 17
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
Pharmacotherapy of Alzheimer’s Disease: Current State and Future Perspectives
Korábečný, J., Zemek, F., Soukup, O., Špilovská, K., Musílek, K., Jun, D., Nepovimová, E., & Kuča, K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50001-5 · Cited by 18
Wu, X., Kosaraju, J., Zhou, W., & Tam, K. Y. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.003 · Cited by 16
“, 2015) and weak clinical efficacy (Salloway et al., 2011).”
BackgroundResultInfluentialNanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
Kanubaddi, K. R., Yang, S.-H., Wu, L.-W., Lee, C., & Weng, C. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s179484 · Cited by 17
Alzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 16
Lyu, D., Lyu, X., Huang, L. T., & Fang, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101959 · Cited by 14
ten Kate, M., Barkhof, F., & Schwarz, A. J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.92 · Cited by 15
Kim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
Ashwini, P., Bodhankar, S. L., Muthal, A., Kumar, D., Pawar, A., & Kulkarni, R. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.016 · Cited by 19
“The inability of GSIs to distinguish between APP and Notch causes critical difficulties of Notch related toxicity, as depicted in Table 2 40,47,83-88 .”
Alzheimer′s disease: Unique markers for diagnosis & new treatment modalities
Aggarwal, N. T., Shah, R. C., & Bennett, D. A. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.169193 · Cited by 19
Rational Design of a Cocktail of Inhibitors against Aβ Aggregation
Gao, L., Yang, W., Li, W., Luo, Y.-Y., Lim, Y., Li, Y., Paul, A., Segal, D., Hong, L., & Li, Y. (2020) · Chemistry - A European Journal · doi:10.1002/chem.201905621 · Cited by 15
Paepe, B. D., Merckx, C., Jarošová, J., Cannizzaro, M., & Bleecker, J. D. (2020) · Biomolecules · doi:10.3390/biom10040521 · Cited by 15
“Trials evaluating the benefits of MI analogues are ongoing in Alzheimer’s disease [32].”
BackgroundLi, Y., Liu, S., & You, C. (2019) · Biotechnology Journal · doi:10.1002/biot.201900191 · Cited by 15
Improving Memory and Cognition in Individuals with Down Syndrome
Rafii, M. S. (2016) · CNS Drugs · doi:10.1007/s40263-016-0353-4 · Cited by 15
Monnard, I., Bénet, T., Jenni, R., Austin, S., Silva‐Zolezzi, I., & Godin, J. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-020-02919-8 · Cited by 14
“Other studies investigated its safety and tolerability [16, 19].”
BackgroundEmerging paradigms in Alzheimer's therapy
Agnes Preethy, H., Rajendran, K., Sukumar, A. J., & Krishnan, U. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176872 · Cited by 15
Bettaney, K. E., Sukumar, P., Hussain, R., Siligardi, G., Henderson, P. J. F., & Patching, S. G. (2012) · Molecular Membrane Biology · doi:10.3109/09687688.2012.729093 · Cited by 13
“…et al. 1996),D-chiro-inositol (2) for treating hyperglycemia and polycystic ovary syndrome (Iuorno et al. 2002); also, scyllo-inositol (3) has recently been used in human clinical trials for the treatment of Alzheimer’s disease (McLaurin et al. 2006, Salloway et al. 2011, www.clinicaltrials. gov).”
MethodAβ 1–42 C-terminus fragment derived peptides prevent the self-assembly of the parent peptide
Bansal, S., Maurya, I. K., Shenmar, K., Yadav, N., Thota, C. K., Kumar, V., Tikoo, K., Chauhan, V. S., & Jain, R. (2017) · RSC Advances · doi:10.1039/c6ra26295c · Cited by 13
Insights from nature: A review of natural compounds that target protein misfolding in vivo
Terry, C. (2020) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2020.10.002 · Cited by 13
S, G. S., Raghu, C. H., & Fayaz, S. M. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210920120612 · Cited by 13
Wu, Y., Kawabata, H., Kita, K., Ishikawa, S., Tanaka, K., & Yoshida, K. (2022) · Microbial Cell Factories · doi:10.1186/s12934-022-01993-0 · Cited by 12
Untangle the mystery behind DS-associated AD – Is APP the main protagonist?
Elangovan, A., Babu, H. W. S., Iyer, M., Gopalakrishnan, A. V., & Vellingiri, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101930 · Cited by 12
Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
Caraci, F., Bosco, P., Leggio, G. M., Malaguarnera, M., Drago, F., Bucolo, C., & Salomone, S. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990141 · Cited by 12
C-Terminal Fragment, Aβ39–42-Based Tetrapeptides Mitigates Amyloid-β Aggregation-Induced Toxicity
Bansal, S., Maurya, I. K., Yadav, N., Thota, C. K., Kumar, V., Tikoo, K., Chauhan, V. S., & Jain, R. (2018) · ACS Omega · doi:10.1021/acsomega.8b01522 · Cited by 12
Intranasal gene therapy for the treatment of neurological disorders
Dhas, N. L., Mehta, T. A., Sharma, S., Garkal, A., Yadav, D., Hariharan, K., Shamjetshabam, B., Khot, S. V., Kudarha, R. R., Bangar, P., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822522-6.00017-5 · Cited by 13
Liang, E., Garzone, P. D., Cedarbaum, J. M., Koller, M., Tran, T. T., Xu, V., Ross, B. D., Jhee, S. S., Ereshefsky, L., Pastrak, A., et al. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.14 · Cited by 13
Modulators of Amyloid β-Protein (Aβ) Self-Assembly
Rahimi, F., Li, H. J., Sinha, S., & Bitan, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00006-x · Cited by 12
“The trial continued with only the low dose, 250 mg/day, which did not lead to significant cognitive or functional improvement (Salloway et al., 2011).”
BackgroundLannfelt, L. (2023) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v128.10316 · Cited by 12
“Another interesting approach is to develop small molecules targeting aggregated Aβ (28, 29).”
BackgroundDenis, P. A. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.09.008 · Cited by 10
“tramiprosate [107], scyllo-inositol [108]).”
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10
Synthesis and decreasing Aβ content evaluation of arctigenin-4-yl carbamate derivatives
Xu, X., Li, C., Lei, M., Zhu, Z., Yan, J., Shen, X., & Hu, L. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.028 · Cited by 10
Drugs under early investigation for the treatment of bipolar disorder
Konstantakopoulos, G., Dimitrakopoulos, S., & Michalopoulou, P. G. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1019061 · Cited by 12
“4 ELND005 ELND005, also known as scyllo-inositol, is an amyloid b peptide aggregation inhibitor under investigation for Alzheimer’s disease [34].”
BackgroundSynthesis of asymmetrically substituted scyllo -inositol
Rodriguez, J., & Walczak, M. A. A. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.06.038 · Cited by 10
Morrone, C. D., Thomason, L. A. M., Brown, M. E., Aubert, I., & McLaurin, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165393 · Cited by 11
Cyclitols: From Basic Understanding to Their Association with Neurodegeneration
Derkaczew, M., Martyniuk, P., Osowski, A., & Wojtkiewicz, J. (2023) · Nutrients · doi:10.3390/nu15092029 · Cited by 9
Current trends and updates in the treatment of Alzheimer's disease
Parikh, N. H., Parikh, P. K., Rao, H. J., Shah, K., Dave, B. P., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00014-5 · Cited by 9
Drug Development for Neurodegenerative Diseases
Nagai, Y., & Minakawa, E. N. (2015) · Springer eBooks · doi:10.1007/978-4-431-54541-5_9 · Cited by 8
Martínez‐Herrera, M., Figueroa-Gerstenmaier, S., López-Camacho, P. Y., Millán‐Pacheco, C., Altamirano, M. Á. B., Mendoza-Franco, G., García-Sierra, F., Zavala-Ocampo, L. M., & Basurto‐Islas, G. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215412 · Cited by 9
Treating Alzheimer’s Disease: Focusing on Neurodegenerative Consequences
Sun, M., & Alkon, D. L. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240479 · Cited by 8
“Scyllo-inositol and tramiprosate, small molecule A (cid:2) binders, failed in clinical trials [86–88].”
Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
Al-Kuraishy, H. M., Sulaiman, G. M., Al-Gareeb, A. I., Mohammed, H. A., Albuhadily, A. K., & Abomughaid, M. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01983-9 · Cited by 8
“Scyllo-inositol, an isomer of endogenous inositol, has potential effects against AD neuropathology by reducing the aggregation and toxicity of Aβ (Salloway et al. 2011).”
Disease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Combination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
Wu, J., Wu, M., Zhang, H., Zhan, X., & Wu, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212338 · Cited by 9
“Several anti-amyloid aggregation agents such as the oral agent scyllo-inositol and the peptidomimetics KLVFF were developed [15,16].”
BackgroundEnfermedad de Alzheimer: nuevas estrategias terapéuticas
Villegas, S. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.05.023 · Cited by 10
Glial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers
Sil, M., Mukherjee, N., Chatterjee, I., Ghosh, A., & Goswami, A. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02379-8 · Cited by 9
“The hyper-phosphorylation of abnormal tau protein, resulting from an imbalance between phosphatase and kinase activity, led to tau pathology (Salloway 2011, Aisen 2011, Orgogozo 2003).”
Jerom, J. P., Madhukumar, S., Nair, R. H., & Narayanan, S. P. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103802 · Cited by 8
Taming Alzheimer's disease: New perspectives, newer horizons.
Sen, D., Majumder, A., Arora, V., Yadu, N., & Chakrabarti, R. (2017) · PubMed Central · Cited by 7
Association between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf089 · Cited by 6
Gao, L., Shuai, Y., Wen, L., Zhang, H., Zhang, Y., & Zhang, X. (2022) · Medicine · doi:10.1097/md.0000000000031637 · Cited by 6
Rai, A., Ojiakor, O. A., & Rylett, R. J. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15904 · Cited by 6
Tanaka, N., Okuda, M., Nishigaki, T., Tsuchiya, N., Kobayashi, Y., Uemura, T., Kumo, S., Sugimoto, H., Miyata, S., & Waku, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235979 · Cited by 6
Rashid, S., Bhat, B. A., & Mehta, G. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202003367 · Cited by 6
Dunn, T., Howlett, S. E., Stanojevic, S., Shehzad, A., Stanley, J., & Rockwood, K. J. (2021) · Journal of Medical Internet Research · doi:10.2196/29219 · Cited by 6
Conti, V., Zarrella, A., Donnarumma, D., Pagano, A., Mazza, I., Stefano, A. D., Gallo, F., Landri, V. D., Pascale, D. D., Manzo, V., et al. (2025) · Applied Sciences · doi:10.3390/app15073513 · Cited by 5
Atanasova, M. (2025) · Pharmaceuticals · doi:10.3390/ph18101457 · Cited by 5
Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States
Aso, E., & Ferrer, I. (2013) · InTech eBooks · doi:10.5772/54783 · Cited by 5
“[35] Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM; ELND005-AD201 Investigators.”
Collet, C., Chrétien, F., Chapleur, Y., & Lamandé‐Langle, S. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.39 · Cited by 5
Metadata
- Authors
- Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., Crans, G., Liang, E., Quinn, G., Bairu, M., Pastrak, A., Cedarbaum, J. M., & For the ELND005-AD201 Investigators
- Affiliations
- Brigham and Women's Hospital (US)
- From the Department of Neurology, Butler Hospital, and Department of Neurology, Alpert Medical School of Brown University (S.S.), Providence, RI; Center for Alzheimer Research and Treatment (R.S.), Brigham and Women's Hospital, Boston, MA; Ontario Shores Centre for Mental Health Sciences (R.K.), Whitby, Canada; Monroe Community Hospital (A.P.P.), University of Rochester Medical Center, Rochester, NY; Departments of Psychiatry and Neurobiology (C.H.v.D.), Yale University School of Medicine, New Haven...
- ORCID
- Venue
- Neurology
- Published
- 2011-09-27
- Volume
- 77
- Issue
- 13
- Pages
- 1253-1262
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC3179648
- OpenAlex
- W2119197968
- Cited by
- 258
- References
- 42
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 11 · 2023: 17 · 2022: 18 · 2021: 14 · 2020: 22 · 2019: 17 · 2018: 13 · 2017: 20 · 2016: 22 · 2015: 21 · 2014: 21 · 2013: 24 · 2012: 17
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Elan
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- scyllo-inositol, Alzheimer's disease, amyloid-beta, cerebrospinal fluid biomarkers, activities of daily living, neuropsychological performance, dose-ranging, drug safety
- MeSH terms
- Administration, Oral, Aged, Aged, 80 and over, Alzheimer Disease, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Inositol, Magnetic Resonance Imaging, Male, Mental Status Schedule, Middle Aged, Peptide Fragments, Platelet Aggregation Inhibitors, Time Factors, Amyloid beta-Peptides, Treatment Outcome, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
